News Archive

June 2018

• Media ReleaseJun 26, 2018

  Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin

  Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy[1] New publication also…
• Media ReleaseJun 18, 2018

  Novartis International AG: Alcon AcrySof® IQ PanOptix® trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery

  Better visual outcomes for patients with the AcrySof IQ PanOptix intraocular lens at near and intermediate distance vision[1]  Detailed findings presented at World Ophthalmology Congress 2018…
• Media ReleaseJun 16, 2018

  Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

  Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable[1]  Patients had a 65% chance of being…
• Media ReleaseJun 15, 2018

  Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life

  Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of…
• Media ReleaseJun 15, 2018

  Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer

  Comparison of Jakavi® (ruxolitinib) vs. best available therapy presented at EHA suggests reduced risk of death in patients with inadequately controlled polycythemia vera (PV)[1]   Additional…
• Media ReleaseJun 15, 2018

  Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis

  Zessly® (infliximab) matched the reference medicine in terms of safety and efficacy at 54 weeks, even in patients who switched from the reference medicine to Zessly[1] Switching from the…
• 
  StoryJun 13, 2018 Discovery

  Women in Science: Kristen Harrington-Smith

  Kristen Harrington-Smith discusses her work as Vice President and Head of CAR-T US at Novartis Oncology.

• Media ReleaseJun 13, 2018

  Novartis presents data to advance understanding of the role of IL-17A and reinforce Cosentyx® leadership in spondyloarthritis

  26 abstracts on Cosentyx® (secukinumab) in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) will be presented at the Annual European Congress of Rheumatology (EULAR 2018)[1]…
• 
  StoryJun 11, 2018 Discovery

  Open resources at Novartis help drive innovation

  With external help from Novartis, an Argentinian researcher was able to begin his search for a new medicine for tuberculosis.

• Media ReleaseJun 07, 2018

  Novartis announces JCO publication of Lutathera® NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs

  Patients reported prolonged maintenance of global health status[1](overall health) Longer time to deterioration (TTD) seen across multiple clinically relevant symptom categories including…
• Media ReleaseJun 06, 2018

  Novartis Schullabor empfängt hunderttausendsten Besucher

  Basel, 6. Juni, 2018 - Mit dem heutigen Besuch einer Schulklasse des Gymnasiums am Münsterplatz in Basel hat das Novartis Schullabor die magische Zahl von über 100'000 Besucherinnen und Besuchern…
• Media ReleaseJun 03, 2018

  Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

  Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line…